1.The expression of K4 in the tissue of oral submucous fibrosis at the early, middle and advanced stages
Gaoxing WEI ; Yingfang WU ; Aihong TAN ; Xiongwei LIU ; Huijuan ZHAO ; Ersha LIU
Journal of Chinese Physician 2015;17(9):1296-1299
Objective To investigate the expressions of cytokeratin/keratin 4 in the buccal tissue of oral submucous fibrosis at the early,middle and advanced stages,explore which role keratin4 (K4) plays in the process and development of oral submucous fibrosis (OSF),and provide evidence for K4 being a promising biomarker to evaluate the development and prognosis of OSF.Methods Ten cases of normal tissues,and 10 cases of OSF tissues with typical early,middle and advanced stages,were selected,respectively.Detect the expression of K4 in the tissue mentioned above through immunohistochemistry and Westem blot.The data was analyzed by statistical means.Results The results of immunohistochemistry showed that K4 was mainly located in cytoplasm,and positive cells with brownish yellow granules were seen in whole epithelial layer of the normal mucosa.The expression of K4 was lower at all stages of OSF than that at the normal tissue with statistical significance (P <0.05).With the aggravation of OSF,the expression of K4 was decreased,difference between early and advanced stage was found to be statistically significant.The results of Western blot also showed that the expression of K4 was lower than that of early,middle and advanced stages of OSF (P < 0.05).With the aggravation of OSF,the expression of K4 was decreased,but the differences between them had no significance (P > 0.05).Conclusions The expression of K4 in OSF tissue of early,middle and advanced stages were decreased compared to normal tissue,respectively.It suggests that K4 might play and important role in the initiation and development of OSF.
2. Effects and associated factors of HIV/AIDS anti-retroviral therapy in Liangshan Yi Autonomous Prefecture, Sichuan Province
Jiali XU ; Chunnong JIKE ; Ye MA ; Gang YU ; Ju WANG ; Ke WANG ; Peng XU ; Qiang LIAO ; Yuhan GONG ; Shiyong ZHONG ; Hu LIU ; Ersha JIKE ; Lin PANG ; Zhongfu LIU
Chinese Journal of Preventive Medicine 2018;52(6):668-672
Objective:
To evaluate the effectiveness and to explore the releated factors of antiretroviral therapy among HIV/AIDS patients in Liangshan Yi Autonomous Prefecture, Sichuan Province.
Methods:
The method of convenience sampling was adopted in July 2017 to select the research objects who were accepted antiretroviral therapy (ART) over 6 months, older than 18 years and had HIV viral load in 2016, totally 400 cases. A retrospective study was used to collect the data, including social demography, medicine use, information of medical service acquisition, their own behaviors and cognition. 395 questionnaires were effectively recovered. χ2 test and logistic regression were performed to examine relationships between factors and effects.
Results:
All of the 395 respondents were Yi-nationality. The average age of all cases was (39.23±7.52) years old and 223 were male (56.5%). Among 395 cases patients who were detect Viral load in 2016, 221 cases were under the number of 400 copies, thze effective rate of ART was 55.9%. Multivariate analysis showed that HIV/AIDS patients who missed the medication during the antiviral therapy had poor antiviral effects. Compared to those who adhered to medication, the treatment-ineffective
3.Comparetive study of CBCT and MSCT in the diagnosis of styloid process syndrome
Chao ZHOU ; Xinchun JIAN ; Anjie MIN ; Lu SUN ; Ersha LIU ; Liling WU
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2016;30(7):557-560
Objective:To investigate the diagnostic value between CBCT and MSCT in the styloid process syndrome. Method:One case with styloid process syndrome is selected examination of CBCT and MSCT in the patient's position of styloid process. The length and the angle of the styloid process in the picture of CBCT and MSCT were measured and had a construct with each other. Result:MSCT is slightly clearer than CBCT in the imaging of styloid process, but there is no obvious difference in the length and angle measurement of styloid process between them. Conclusion:Except for MSCT, CBCT is another important means in the diagnosis of styloid process syndrome, CBCT has a great clinical application value.
4.FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy.
Shaoxing GUAN ; Xi CHEN ; Youhao CHEN ; Guohui WAN ; Qibiao SU ; Heng LIANG ; Yunpeng YANG ; Wenfeng FANG ; Yan HUANG ; Hongyun ZHAO ; Wei ZHUANG ; Shu LIU ; Fei WANG ; Wei FENG ; Xiaoxu ZHANG ; Min HUANG ; Xueding WANG ; Li ZHANG
Acta Pharmaceutica Sinica B 2022;12(9):3639-3649
Hepatotoxicity is a common side effect for patients treated with gefitinib, but the related pathogenesis is unclear and lacks effective predictor and management strategies. A multi-omics approach integrating pharmacometabolomics, pharmacokinetics and pharmacogenomics was employed in non-small cell lung cancer patients to identify the effective predictor for gefitinib-induced hepatotoxicity and explore optional therapy substitution. Here, we found that patients with rs4946935 AA, located in Forkhead Box O3 (FOXO3) which is a well-known autophagic regulator, had a higher risk of hepatotoxicity than those with the GA or GG variant (OR = 18.020, 95%CI = 2.473 to 459.1784, P = 0.018) in a gefitinib-concentration dependent pattern. Furthermore, functional experiments identified that rs4946935_A impaired the expression of FOXO3 by inhibiting the promotor activity, increasing the threshold of autophagy initiation and inhibiting the autophagic activity which contributed to gefitinib-induced liver injury. In contrast, erlotinib-induced liver injury was independent on the variant and expression levels of FOXO3. This study reveals that FOXO3 mutation, leading to autophagic imbalance, plays important role in gefitinib-induced hepatotoxicity, especially for patients with high concentration of gefitinib. In conclusion, FOXO3 mutation is an effective predictor and erlotinib might be an appropriately and well-tolerated treatment option for patients carrying rs4946935 AA.